Travere Therapeutics (TVTX) Cash from Operations (2011 - 2026)

Travere Therapeutics has reported Cash from Operations for 16 years, with the latest figure at 40366000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 4.33% year-over-year to 40366000.0; the trailing twelve-month figure through Mar 2026 stood at 39612000.0 (up 125.84% YoY), and the FY2025 full-year result was 37784000.0, up 116.43% from the prior year.
• Cash from Operations for Q1 2026 stood at 40366000.0, down from 60678000.0 in the prior quarter.
• The five-year high for Cash from Operations was 60678000.0 in Q4 2025, with the low at 118902000.0 in Q1 2024.
• Historically, Cash from Operations has averaged 48165235.29 across 5 years, with a median of 42507000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 666.59% — and 2025, when it surged 314.65%.
• Travere Therapeutics' Cash from Operations stood at 76704000.0 in 2022, then grew by 16.08% to 64373000.0 in 2023, then surged by 56.09% to 28269000.0 in 2024, then surged by 314.65% to 60678000.0 in 2025, then sank by 166.52% to 40366000.0 in 2026.
• The last three Cash from Operations figures came in at 40366000.0 (Q1 2026), 60678000.0 (Q4 2025), and 14317000.0 (Q3 2025), per Business Quant data.